Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
334 of 389 (86%) registered Norwegians with coagulation factor defects were screened for antibodies to the human immunodeficiency virus (HIV) in 1985/1986. 21 persons were confirmed anti-HIV positive. They were all persons with clinically severe haemophilia A and represent 18.4% of 114 tested persons with severe haemophilia A. 3 patients have developed AIDS, 3 have persistent generalized lymphadenopathy. At least 8 of the 21 seropositive persons (38%) have been infected through lyophilized cryoprecipitates prepared from volunteer plasma donated in national blood banks. None of 10 heterosexual partners have antibodies to HIV. We conclude that the policy of using small-pooled lyophilized cryoprecipitates instead of commercial concentrates has reduced HIV-infection among Norwegian haemophiliacs. Today, the prevalence of HIV antibodies in the haemophilia population in Norway is among the lowest in Western Europe.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1600-0609.1987.tb00162.x | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!